SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)
Latest Information Update: 25 Oct 2022
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SEESAW
- Sponsors Boehringer Ingelheim
- 01 Aug 2022 Results published in the Diabetes, Obesity and Metabolism
- 25 Sep 2020 Primary endpoint (Change from baseline in Total PYY at 24 weeks) has not been met, as per results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes